Health and Healthcare
Icahn, ImClone, Bristol-Myers... A 3-Way Marriage (IMCL, BMY)
Published:
Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share.
As per the filing:
- James M. Cornelius, Chairman and Chief Executive Officer of BMS, called Carl C. Icahn, Chairman of the Board of ImClone, to convey an offer by BMS to enter into an agreement to acquire ImClone for $60 per share in cash (the “BMS Offer”). The BMS Offer represents a premium of approximately 30% over the closing price of ImClone common stock on July 30, 2008, a premium of approximately 40% over the one-month average closing price of ImClone common stock, and a premium in excess of 40% over the three-month and one-year average closing prices of ImClone common stock. The BMS Offer was authorized by the BMS Board of Directors.
Yep, another biotech looks to be disappearing.
Jon C. Ogg
July 31, 2008
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
